Literature DB >> 22950997

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Philip Rosen1, David Pfister, Denise Young, Gyorgy Petrovics, Yongmei Chen, Jennifer Cullen, Diana Böhm, Sven Perner, Albert Dobi, David G McLeod, Isabell A Sesterhenn, Shiv Srivastava.   

Abstract

OBJECTIVE: To systematically evaluate the ETS-related gene (ERG) alterations in the multifocal tumor context using whole-mount prostatectomy specimens from African and Caucasian American patients matched for age, pathologic grade and stage. Oncogenic activation of the ERG is the most common early genomic alteration in patients with prostate cancer (CaP) in Western countries. However, ERG alterations have not been systematically examined in African American patients with a known greater risk of CaP incidence and mortality. <br> METHODS: ERG oncoprotein expression was analyzed in 91 Caucasian and 91 African American patients with CaP, who were matched for age, Gleason score, and pathologic stage. A unique aspect of the present study was the evaluation of ERG in whole-mount prostatectomy sections, minimizing sampling bias and allowing the careful assessment of the ERG in the multifocal tumor context of CaP. <br> RESULTS: The frequency of ERG-positive prostate tumors was significantly greater among Caucasian Americans than among African Americans when assessed in all tumor foci (41.9% vs 23.9%, P < .0001). A markedly greater frequency of ERG oncoprotein expression was noted between the index tumors of the Caucasian Americans (63.3%) and those of the African Americans (28.6%). Also, in the African American patients, the higher grade index tumors were predominantly ERG negative. <br> CONCLUSION: ERG typing of CaP established a major difference between the index tumors of Caucasian and African American patients. ERG-negative index tumors might indicate a less favorable outcome for African American patients. The results of the present study underscore that typing of CaP for the ERG could enhance our understanding of the biologic differences between the examined ethnic groups.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22950997      PMCID: PMC3462242          DOI: 10.1016/j.urology.2012.07.001

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  15 in total

1.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

Review 2.  Prostate cancer and race.

Authors:  Otis W Brawley; Ashesh B Jani; Veraj Master
Journal:  Curr Probl Cancer       Date:  2007 May-Jun       Impact factor: 3.187

3.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

Authors:  Bo Han; Rohit Mehra; Saravana M Dhanasekaran; Jindan Yu; Anjana Menon; Robert J Lonigro; Xiaosong Wang; Yusong Gong; Lei Wang; Sunita Shankar; Bharathi Laxman; Rajal B Shah; Sooryanarayana Varambally; Nallasivam Palanisamy; Scott A Tomlins; Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

4.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

5.  ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Authors:  Yohei Miyagi; Takeshi Sasaki; Kiyoshi Fujinami; Jinyu Sano; Yutaka Senga; Takeshi Miura; Yoichi Kameda; Yuji Sakuma; Yoshiyasu Nakamura; Masaoki Harada; Eiju Tsuchiya
Journal:  Mod Pathol       Date:  2010-08-06       Impact factor: 7.842

6.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Authors:  Gyorgy Petrovics; Aijun Liu; Syed Shaheduzzaman; Bungo Furusato; Bungo Furasato; Chen Sun; Yongmei Chen; Martin Nau; Lakshmi Ravindranath; Yidong Chen; Albert Dobi; Vasantha Srikantan; Isabell A Sesterhenn; David G McLeod; Maryanne Vahey; Judd W Moul; Shiv Srivastava
Journal:  Oncogene       Date:  2005-05-26       Impact factor: 9.867

7.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Authors:  J W Moul; I A Sesterhenn; R R Connelly; T Douglas; S Srivastava; F K Mostofi; D G McLeod
Journal:  JAMA       Date:  1995-10-25       Impact factor: 56.272

8.  Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Authors:  Kevin R Rice; Yongmei Chen; Amina Ali; Eric J Whitman; Amy Blase; Mona Ibrahim; Sally Elsamanoudi; Stephen Brassell; Bungo Furusato; Norbert Stingle; Isabell A Sesterhenn; Gyorgy Petrovics; Siobhan Miick; Harry Rittenhouse; Jack Groskopf; David G McLeod; Shiv Srivastava
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

9.  ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

Authors:  M Braun; D Goltz; D Adler; W Vogel; D Böhm; V Scheble; K Sotlar; F Fend; S-H Tan; A Dobi; G Kristiansen; N Wernert; S Perner
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-01-10       Impact factor: 5.554

10.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

View more
  45 in total

Review 1.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

3.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

Authors:  Said Rahim; Aykut Uren
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

4.  Evaluation of ERG responsive proteome in prostate cancer.

Authors:  Shyh-Han Tan; Bungo Furusato; Xueping Fang; Fang He; Ahmed A Mohamed; Nicholas B Griner; Kaneeka Sood; Sadhvi Saxena; Shilpa Katta; Denise Young; Yongmei Chen; Taduru Sreenath; Gyorgy Petrovics; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Satya Saxena; Shiv Srivastava
Journal:  Prostate       Date:  2013-09-21       Impact factor: 4.104

5.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

6.  ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.

Authors:  Nicholas B Griner; Denise Young; Pankaj Chaudhary; Ahmed A Mohamed; Wei Huang; Yongmei Chen; Taduru Sreenath; Albert Dobi; Gyorgy Petrovics; Jamboor K Vishwanatha; Isabell A Sesterhenn; Shiv Srivastava; Shyh-Han Tan
Journal:  Mol Cancer Res       Date:  2014-10-24       Impact factor: 5.852

7.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

8.  Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.

Authors:  Rebecca E Graff; Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Kathryn L Penney; Kathryn M Wilson; Sarah C Markt; Claire H Pernar; Amparo G Gonzalez-Feliciano; Mingyang Song; Rosina T Lis; Daniel R Schmidt; Matthew G Vander Heiden; Michelangelo Fiorentino; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

9.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Authors:  Francesca Khani; Juan Miguel Mosquera; Kyung Park; Mirjam Blattner; Catherine O'Reilly; Theresa Y MacDonald; Zhengming Chen; Abhishek Srivastava; Ashutosh K Tewari; Christopher E Barbieri; Mark A Rubin; Brian D Robinson
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

Review 10.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.